CWA
ABUS icon

Cura Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

Cura Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72K Hold
15,000
– – 0.03% 138
2026
Q1 		$67.5K Hold
15,000
– – 0.03% 125
2025
Q4 		$72.2K Hold
15,000
– – 0.03% 141
2025
Q3 		$68.1K Hold
15,000
– – 0.03% 126
2025
Q2 		$46.4K Hold
15,000
– – 0.02% 115
2025
Q1 		$52.4K Hold
15,000
– – 0.02% 104
2024
Q4 		$49K Buy
+15,000
New +$55.2K 0.02% 96

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cura Wealth Advisors's ABUS Position: Q2 2026 in Review

Cura Wealth Advisors held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 15,000 shares worth $72K. The position accounts for 0.03% of the portfolio, ranked #138.

Cura Wealth Advisors first reported a position in ABUS in Q4 2024 and has held it in 7 quarters since. The position peaked at $72.2K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Cura Wealth Advisors held 15,000 shares of Arbutus Biopharma worth $72K as of Q2 2026.
  • Cura Wealth Advisors left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up 0.03% of Cura Wealth Advisors's portfolio in Q2 2026, its #138 holding.
  • Cura Wealth Advisors first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 7 quarters since.
  • Cura Wealth Advisors's Arbutus Biopharma position peaked at $72.2K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Cura Wealth Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.